中国临床药理学杂志2025，Vol.41Issue(21)：3014-3018,5.DOI:10.13699/j.cnki.1001-6821.2025.21.003
德谷胰岛素利拉鲁肽联合二甲双胍治疗胰岛素及口服降糖药控制不佳2型糖尿病患者的临床研究
Clinical trial of insulin degludec and liraglutide combination with metformin in the treatment of type 2 diabetes mellitus patients with poorly controlled insulin and oral hypoglycemic drugs
摘要
Abstract
Objective To observe the clinical efficacy and safety of insulin degludec and liraglutide combination with metformin tablets in the treatment of type 2 diabetes mellitus(T2DM)patients with poorly controlled insulin and oral hypoglycemic drugs.Methods The T2DM patients with poor control of insulin and oral hypoglycemic drugs were randomly divided into control group and treatment group according to the queue method.Both groups of patients received metformin tablets for basic treatment.On this basis,the control group was given premixed insulin aspartic 30 injection multiple times a day for treatment.The initial injection dose was 0.2-0.4 U·kg-1·d-1,twice a day,adjusted according to the blood glucose level,once every 3-5 days,with an increase or decrease of 1-4 U each time.The treatment group was treated with insulin degludec and liraglutide injection.The initial injection was 10 to 16 dose units,administered subcutaneously once a day.The dose was adjusted every 1 to 2 weeks based on the blood glucose level,with an increase or decrease of 2 to 4 dose units each time.Both groups of patients were treated for 3 months.The clinical efficacy,blood glucose level,lipid metabolism level,pancreatic islet function and safety of the two groups of patients were compared.Results A total of 40 cases in the control group and 40 cases in the treatment group were enrolled.After treatment,the total effective rates of the treatment group and the control group were 97.50％(39 cases/40 cases)and 80.00％(32 cases/40 cases),the difference was statistically significant(P＜0.05).After 3 months of treatment,the glycosylated hemoglobin levels of the treatment group and the control group were(6.14±1.03)％and(7.20±1.08)％,respectively;the fasting blood glucose levels were(6.25±1.34)and(7.82±1.26)mmol·L-1,respectively;the 2 h postprandial blood glucose levels were(6.37±0.64)and(7.15±0.67)mmol·L-1,respectively;the triglyceride levels were(1.87±0.62)and(2.64±0.79)mmol·L-1,respectively;the serum total cholesterol levels were(4.53±0.62)and(5.18±0.76)mmol·L-1,respectively;and the fasting insulin levels were(7.16±0.71)and(8.56±0.94)μmol·L-1,respectively;islet β cell function index levels were(58.36±5.87)％and(50.72±6.14)％,respectively;while insulin resistance index levels were 1.52±0.44 and 2.09±0.47,respectively,the differences were statistically significant between the two groups(all P＜0.05).The main adverse drug reactions in the treatment group were gastrointestinal reactions,dizziness,increased heart rate and hypoglycemia,while those in the control group were mainly gastrointestinal reactions,dizziness and hypoglycemia.The total incidences of adverse drug reactions in the treatment group and the control group were 15.00％and 12.50％,respectively,and there was no statistically significant difference(P＞0.05).Conclusion Insulin degludec and liraglutide injection has shown significant clinical efficacy in the treatment of T2DM with poor control of insulin and oral hypoglycemic drugs.It can effectively control patients' blood glucose and lipid metabolism levels,improve pancreatic function,and has good safety.关键词
德谷胰岛素利拉鲁肽注射液/二甲双胍片/2型糖尿病/血糖/安全性评价Key words
insulin degludec and liraglutide injection/metformin tablet/type 2 diabetes mellitus/blood glucose/safety分类
医药卫生引用本文复制引用
金佳妮,武红梅,王斌,何圣清,龙爱梅,潘霞明,孟莞瑞,邓丽萍..德谷胰岛素利拉鲁肽联合二甲双胍治疗胰岛素及口服降糖药控制不佳2型糖尿病患者的临床研究[J].中国临床药理学杂志,2025,41(21):3014-3018,5.基金项目
广东省医学科研基金资助项目(A2024404) （A2024404）
